 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LML134 / Novartis
Clinical, Journal: The discovery of LML134, a histamine H3 receptor inverse agonist for the clinical treatment of excessive sleep disorders. (Pubmed Central) - Apr 10, 2020
No abstract available
- ||| LML134 / Novartis
Trial termination: A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder (clinicaltrials.gov) - Feb 16, 2019
P2, N=24, Terminated, Sponsor: Novartis Pharmaceuticals
No abstract available Completed --> Terminated; CLML134X2201 was terminated due to business reasons and not to safety findings
- | LML134 / Novartis
Trial completion, Enrollment change: A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder (clinicaltrials.gov) - Oct 2, 2018
P2, N=24, Completed, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; CLML134X2201 was terminated due to business reasons and not to safety findings Recruiting --> Completed | N=46 --> 24
- | LML134 / Novartis
Trial completion date, Trial primary completion date: A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder (clinicaltrials.gov) - Aug 23, 2018
P2, N=46, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=46 --> 24 Trial completion date: Nov 2019 --> Sep 2018 | Trial primary completion date: Nov 2019 --> Sep 2018
- | LML134 / Novartis
Trial completion date, Trial primary completion date: A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder (clinicaltrials.gov) - Jun 14, 2018
P2, N=46, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Nov 2019 --> Sep 2018 | Trial primary completion date: Nov 2019 --> Sep 2018 Trial completion date: Jun 2018 --> Nov 2019 | Trial primary completion date: Jun 2018 --> Nov 2019
- | LML134 / Novartis
Enrollment open: A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder (clinicaltrials.gov) - Jul 24, 2017
P2, N=46, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jun 2018 --> Nov 2019 | Trial primary completion date: Jun 2018 --> Nov 2019 Not yet recruiting --> Recruiting
- | LML134 / Novartis
New P2 trial: A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder (clinicaltrials.gov) - May 4, 2017
P2, N=46, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| LML134 / Novartis
Trial completion: First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers (clinicaltrials.gov) - Apr 26, 2016
P1, N=133, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| LML134 / Novartis
Enrollment open: First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers (clinicaltrials.gov) - Jun 1, 2015
P1, N=152, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- || LML134 / Novartis
Trial primary completion date: First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers (clinicaltrials.gov) - Feb 11, 2015
P1, N=152, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Dec 2015
- ||| LML134 / Novartis
New P1 trial: First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers (clinicaltrials.gov) - Jan 8, 2015
P1, N=152, Not yet recruiting, Sponsor: Novartis Pharmaceuticals